Outcome of Board meeting
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Alembic Pharmaceuticals reported standalone revenue of Rs 6,651 crore for FY2026, up 10.3% from Rs 6,033 crore in FY2025. Profit after tax grew 27.3% to Rs 640 crore versus Rs 503 crore previously. Consolidated revenue was Rs 7,345 crore (up 10.1%) with PAT of Rs 675 crore (up 15.7%). Net profit margin expanded from 8.34% to 9.63% on standalone basis. The Board recommended dividend of Rs 12 per share (600%) versus Rs 11 (550%) earlier. Key exceptional items included Rs 48.64 crore charge for labour code implementation, Rs 18.35 crore write-down on Sikkim facility assets held for sale, and Rs 100.27 crore deferred tax asset recognition from tax rate changes. Statutory auditors issued unmodified opinion on both standalone and consolidated results.
Strong profitability growth with PAT up 27% on standalone basis and margin expansion signals operational efficiency gains. Increased dividend demonstrates confidence in financial health. Conservative debt levels (Debt-Equity 0.20) and positive operating cash flow of Rs 809 crore support shareholder returns.